annb0t
Top 20
Mesoblast Limited
Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohnâs and Colitis Organisation (ECCO)
NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from an interim analysis of the first patient cohort in the randomized, controlled study of remestemcel-L by direct endoscopic delivery to area...
>>> Read more: Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohnâs Colitis After Direct Injection of Remestemcel-L by Colonoscopy
Results of First Patient Cohort from Randomized Controlled Study Presented at Congress of European Crohnâs and Colitis Organisation (ECCO)
NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from an interim analysis of the first patient cohort in the randomized, controlled study of remestemcel-L by direct endoscopic delivery to area...
>>> Read more: Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohnâs Colitis After Direct Injection of Remestemcel-L by Colonoscopy
